These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6314884)

  • 1. Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
    Kowalsky SF; Echols RM; Venezia AR; Andrews EA
    Antimicrob Agents Chemother; 1983 Aug; 24(2):151-5. PubMed ID: 6314884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination kinetics of ceftizoxime in humans with and without renal insufficiency.
    Ohkawa M; Okasho A; Sugata T; Kuroda K
    Antimicrob Agents Chemother; 1982 Aug; 22(2):308-11. PubMed ID: 6100425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis.
    Gambertoglio JG; Alexander DP; Barriere SL
    Antimicrob Agents Chemother; 1984 Dec; 26(6):845-9. PubMed ID: 6098220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis.
    Burgess ED; Blair AD
    Antimicrob Agents Chemother; 1983 Aug; 24(2):237-9. PubMed ID: 6314887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of ceftizoxime with and without probenecid].
    Adam D; Timmler R
    Arzneimittelforschung; 1982; 32(4):416-9. PubMed ID: 6285937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of multiple doses of ceftizoxime and their influence on fecal flora.
    Lode H; Warns H; Kemmerich B; Knothe H; Koeppe P
    Eur J Clin Microbiol; 1983 Apr; 2(2):116-21. PubMed ID: 6305648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of ceftizoxime, a new cephalosporin. Single-dose study.
    Nakashima N; Suzuki K; Hashimoto H; Nishijima K
    J Clin Pharmacol; 1981 Oct; 21(10):388-95. PubMed ID: 6273456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjects.
    Peterson LR; Gerding DN; Van Etta LL; Eckfeldt JH; Larson TA
    Antimicrob Agents Chemother; 1982 Nov; 22(5):878-81. PubMed ID: 6295270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of intravenous ceftizoxime in patients on continuous ambulatory peritoneal dialysis.
    Johnson CA; Zimmerman SW; Bayer W; Craig WA
    Clin Nephrol; 1985 Mar; 23(3):120-4. PubMed ID: 3857136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
    Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ceftizoxime.
    Gundert-Remy U; Hildebrandt R; Stiehl A; Schlegel P
    Eur J Clin Pharmacol; 1985; 28(4):463-7. PubMed ID: 3861322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ceftizoxime.
    Cutler RE; Blair AD; Burgess ED; Parks D
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():91-7. PubMed ID: 6296034
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
    Drusano GL; Weir M; Forrest A; Plaisance K; Emm T; Standiford HC
    Antimicrob Agents Chemother; 1987 Jun; 31(6):860-4. PubMed ID: 3619418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.
    Bolton WK; Scheld WM; Spyker DA; Overby TL; Sande MA
    Antimicrob Agents Chemother; 1980 Dec; 18(6):933-8. PubMed ID: 6453555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Ozawa Y
    Antimicrob Agents Chemother; 1984 Nov; 26(5):647-51. PubMed ID: 6097172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of ceftizoxime compared with that of cefamandole.
    Neu HC; Srinivasan S
    Antimicrob Agents Chemother; 1981 Sep; 20(3):366-9. PubMed ID: 6272631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.
    Guay DR; Meatherall RC; Harding GK; Brown GR
    Antimicrob Agents Chemother; 1986 Sep; 30(3):485-90. PubMed ID: 3777912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis.
    Gross ML; Somani P; Ribner BS; Raeader R; Freimer EH; Higgins JT
    Clin Pharmacol Ther; 1983 Nov; 34(5):673-80. PubMed ID: 6313276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.